scholarly journals The drug treatment of parkinson’s disease

1984 ◽  
Vol 22 (10) ◽  
pp. 37-40
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Drug Treatment ◽  
Dopamine Agonist ◽  
Monoamine Oxidase B ◽  
Anticholinergic Drugs ◽  
Decarboxylase Inhibitor ◽  
Progressive Degeneration ◽  
The Brain

The symptoms of idiopathic Parkinson’s disease are due mainly to progressive degeneration of the dopaminergic nigro-striatal pathways in the brain. The drugs which can help fall into five categories: dopamine replacement, using dopa with a decarboxylase inhibitor; a dopamine agonist, bromocriptine;1 selegiline, recently introduced, which inhibits monoamine oxidase B; anticholinergic drugs; and amantadine.2 This article discusses recent ideas about the management of Parkinson’s disease, particularly about levodopa dosage, bromocriptine and selegiline.

scholarly journals VIRTUAL SCREENING OF GINKGO BILOBA FOR THERAPEUTIC POTENTIALS AGAINST PARKINSON’S DISEASE

2016 ◽  
Vol 3 (1) ◽  
pp. 6-11
Author(s):  
Kavitha V ◽  
Jone Kirubavathy S ◽  
Sivaramkumar M.S ◽  
Velmurugan R
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Docking ◽  
Monoamine Oxidase ◽  
Ginkgo Biloba ◽  
Neurodegenerative Disorder ◽  
Docking Studies ◽  
Monoamine Oxidase B ◽  
Mao B ◽  
The Brain

Parkinson's disease (PD) is a neurodegenerative disorder that affects 2% of the population older than 60 years. Monoamine Oxidase B (MAO-B) inhibitors improve the symptoms of Parkinson's disease and can delay the progress. Inhibition of MAO-B, further prevent breakdown of dopamine in the brain and reducethe motor symptoms associated with PD. Ginkgo biloba has a number of therapeutic properties and contains phytonutrients that helps in improvement of neurological disorders. In present study, phytonutrients of Ginkgo biloba namely Myricetin, Quercetin, Isorhamnetin, Kaempferol, Ginkgolides A-C, and Ginkgolide J were selected for Molecular docking against Monoamine Oxidase-B enzyme. The Molecular Docking studies were performed using Autodock 4.2 and interaction between MAO-B and compounds were analyzed. The efficiency of the compound was screened based on the binding energy existing between the protein and inhibitor. The docking studies show that the phytochemicals of Ginkgo biloba against MAO-B were quite effective. The potential compound can be subjected to further clinical trials and can be an alternative in the future treatment of Parkinson’s disease.

Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease

2009 ◽  
Vol 34 (8) ◽  
pp. 1427-1432 ◽  
Author(s):  
Maroof Husain ◽  
Rakesh Shukla ◽  
Madhu Dikshit ◽  
Pradeep K. Maheshwari ◽  
Devika Nag ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease ◽  
Platelet Monoamine Oxidase

scholarly journals Monoamine oxidase B inhibitors for early Parkinson's disease

2005 ◽  
Author(s):  
Kristian Turnbull ◽  
Robert Caslake ◽  
Angus Macleod ◽  
Natalie Ives ◽  
Rebecca Stowe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Early Parkinson’S Disease

▼ Safinamide for Parkinson’s disease

2018 ◽  
Vol 56 (5) ◽  
pp. 54-57
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Motor Fluctuations ◽  
Daily Activities ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Idiopathic Parkinson’S Disease ◽  
Mao B ◽  
Idiopathic Parkinson's Disease

▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.

Sign in / Sign up

Export Citation Format

Share Document